Prashant Subedi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Prashant Subedi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Amrendra Mandal
Internal Medicine, Interfaith Medical Center, Brooklyn, USA
1 shared publication Bickram Pradhan
Department of Gastroenterology and Hepatology, B.P. Koirala Institute of Health Sciences, Dharan 56700, Nepal
1 shared publicationDenis Peeyush
Department of Gastroenterology and Hepatology, B.P. Koirala Institute of Health Sciences, Dharan 56700, Nepal
1 shared publicationMukesh S. Paudel
Gastroenterology, National Academy of Medical Sciences, Kathmandu, NPL
1 shared publicationPrakash Sapkota
Department of Gastroenterology and Hepatology, B.P. Koirala Institute of Health Sciences, Dharan 56700, Nepal
1 shared publicationRajesh Kumar Mandal
Department of Gastroenterology and Hepatology, B.P. Koirala Institute of Health Sciences, Dharan 56700, Nepal
1 shared publication
Latest Publications
- Open Access
- 7 July 2025
- Published by Nepal Journals Online (JOL) in Journal of Advances in Internal Medicine
- Vol. 14 (1) , 1-6
Infections in patients admitted with decompensated chronic liver disease in a tertiary level hospital
INTRODUCTION Infection is one of the major complications leading to hospital admission and mortality in patients with decompensated chronic liver disease (CLD). This study aims to determine the clinical profile and outcome of these patients which is very limited in our part of the world. METHODS In this prospective observational study; we included all 184 patients from January 2025 to April 2025 with decompensated CLD admitted in Gastroenterology and Hepatology ward of B.P. Koirala Institute of Health Sciences. The clinical profile and outcomes of these patients were evaluated and analyzed. Common scores used in patients with cirrhosis including CTP (Child-Turcotte Pugh), MELD-Na (Model for end-stage liver disease) and SOFA (Sequential organ failure assessment) score were evaluated for their role in predicting mortality. RESULTS The prevalence of infection in CLD was found to be 37.5% with male predominance of 53.8%; mean age was 51.42 years (SD: 11.85). Alcohol related cirrhosis was the commonest etiology and other etiology included autoimmune hepatitis, chronic HCV, chronic HBV, Wilson’s disease, metabolic syndrome associated steatotic liver disease (MASLD), PSC related and cryptogenic. Spontaneous bacterial peritonitis was the most common infection with 26 (37.7%) followed by urinary tract infection, pneumonia and skin and soft tissue infection. Infection was significantly associated with longer hospital stay, higher MELD-Na, CTP and SOFA scores of patients. Area under the curve for MELD-Na had the highest discriminative ability to predict mortality with cut-off values of 22.5 with sensitivity of 93.75% and specificity of 62.26%. The in-hospital mortality in patients with decompensated CLD with infection was 23.2%. CONCLUSION Infection in decompensated CLD patients is a major predictor of adverse outcomes including mortality. Early identification and aggressive management of infection in this group of patients is needed to prevent adverse outcomes.
- 7 July 2025
- Published by Nepal Journals Online (JOL) in Journal of Advances in Internal Medicine
- Vol. 14 (1) , 1-6
Open AccessInfections in patients admitted with decompensated chronic liver disease in a tertiary level hospital
INTRODUCTION Infection is one of the major complications leading to hospital admission and mortality in patients with decompensated chronic liver disease (CLD). This study aims to determine the clinical profile and outcome of these patients which is very limited in our part of the world. METHODS In this prospective observational study; we included all 184 patients from January 2025 to April 2025 with decompensated CLD admitted in Gastroenterology and Hepatology ward of B.P. Koirala Institute of Health Sciences. The clinical profile and outcomes of these patients were evaluated and analyzed. Common scores used in patients with cirrhosis including CTP (Child-Turcotte Pugh), MELD-Na (Model for end-stage liver disease) and SOFA (Sequential organ failure assessment) score were evaluated for their role in predicting mortality. RESULTS The prevalence of infection in CLD was found to be 37.5% with male predominance of 53.8%; mean age was 51.42 years (SD: 11.85). Alcohol related cirrhosis was the commonest etiology and other etiology included autoimmune hepatitis, chronic HCV, chronic HBV, Wilson’s disease, metabolic syndrome associated steatotic liver disease (MASLD), PSC related and cryptogenic. Spontaneous bacterial peritonitis was the most common infection with 26 (37.7%) followed by urinary tract infection, pneumonia and skin and soft tissue infection. Infection was significantly associated with longer hospital stay, higher MELD-Na, CTP and SOFA scores of patients. Area under the curve for MELD-Na had the highest discriminative ability to predict mortality with cut-off values of 22.5 with sensitivity of 93.75% and specificity of 62.26%. The in-hospital mortality in patients with decompensated CLD with infection was 23.2%. CONCLUSION Infection in decompensated CLD patients is a major predictor of adverse outcomes including mortality. Early identification and aggressive management of infection in this group of patients is needed to prevent adverse outcomes.
- Open Access
- 5 December 2021
- Published by Springer Nature in Cureus
- Vol. 13 (12) , e20186
Comparison of Characteristics and Inpatient Outcomes of Patients With Inflammatory Bowel Disease and Colon Cancer: A Propensity-Based Nationwide Inpatient Sample Study
Introduction Patients with inflammatory bowel diseases (IBDs) frequently develop colon cancer. Previous studies have identified the association between IBD and colon cancer. In this study, we explored the characteristics and outcomes of IBD patients with colon cancer admitted to the hospitals of the United States. Methods Patients who were hospitalized patients with diagnoses of IBD and colon cancer were compared with patients with IBD without colon cancer. The data were extracted from the Nationwide Inpatient Sample (NIS) from January 2016 to December 2017. Comparisons were made with regards to mortality, complications, in-hospital stay, and cost of treatment between the two groups. Results We identified 1,82,025 hospitalizations from January 2016 to December 2017 admitted with a diagnosis of IBD. Of these, 181,560 patients had IBD without colon cancer, and 465 patients had IBD with colon cancer. No statistically significant difference was observed with regards to the in-hospital mortality between the two groups. There were higher odds of acute kidney injury (AKI) (OR 1.54, 95% CI 6.6-9.8; p=0.00), colectomy (OR 1.2, 95% CI 1.3-2.5; p=0.0) and lower gastrointestinal bleeding (LGIB) (OR 1.6, 95% CI 1.8-3.7; p=0.04) in patients with IBD and colon cancer. A longer length of stay (7.1 +/- 6.9 vs.5.0 +/- 5.6, p=0.00) and higher mean total charge ($20,283 vs. $12,166, p=0.00) were observed in patients with IBD with colon cancer. Conclusions Patients with IBD-associated colon cancer appear to have higher complication rates, higher costs, and more extended hospital stays. Therefore, early identification and management of complications related to IBD among patients with colon cancer are particularly crucial to reduce morbidity as well as the cost of hospitalization and treatment.
- 5 December 2021
- Published by Springer Nature in Cureus
- Vol. 13 (12) , e20186
Open AccessComparison of Characteristics and Inpatient Outcomes of Patients With Inflammatory Bowel Disease and Colon Cancer: A Propensity-Based Nationwide Inpatient Sample Study
Introduction Patients with inflammatory bowel diseases (IBDs) frequently develop colon cancer. Previous studies have identified the association between IBD and colon cancer. In this study, we explored the characteristics and outcomes of IBD patients with colon cancer admitted to the hospitals of the United States. Methods Patients who were hospitalized patients with diagnoses of IBD and colon cancer were compared with patients with IBD without colon cancer. The data were extracted from the Nationwide Inpatient Sample (NIS) from January 2016 to December 2017. Comparisons were made with regards to mortality, complications, in-hospital stay, and cost of treatment between the two groups. Results We identified 1,82,025 hospitalizations from January 2016 to December 2017 admitted with a diagnosis of IBD. Of these, 181,560 patients had IBD without colon cancer, and 465 patients had IBD with colon cancer. No statistically significant difference was observed with regards to the in-hospital mortality between the two groups. There were higher odds of acute kidney injury (AKI) (OR 1.54, 95% CI 6.6-9.8; p=0.00), colectomy (OR 1.2, 95% CI 1.3-2.5; p=0.0) and lower gastrointestinal bleeding (LGIB) (OR 1.6, 95% CI 1.8-3.7; p=0.04) in patients with IBD and colon cancer. A longer length of stay (7.1 +/- 6.9 vs.5.0 +/- 5.6, p=0.00) and higher mean total charge ($20,283 vs. $12,166, p=0.00) were observed in patients with IBD with colon cancer. Conclusions Patients with IBD-associated colon cancer appear to have higher complication rates, higher costs, and more extended hospital stays. Therefore, early identification and management of complications related to IBD among patients with colon cancer are particularly crucial to reduce morbidity as well as the cost of hospitalization and treatment.